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Abstract
Background:  Controversy still exists regarding the long-term outcome of patients whose
uninvolved lymph node stations are not prophylactically irradiated for non-small cell lung cancer
(NSCLC) treated with definitive radiotherapy. To determine the frequency of elective nodal failure
(ENF) and in-field failure (IFF), we examined a large cohort of patients with NSCLC staged with
positron emission tomography (PET)/computed tomography (CT) and treated with 3-dimensional
conformal radiotherapy (3D-CRT) that excluded uninvolved lymph node stations.
Methods: We retrospectively reviewed the records of 115 patients with non-small cell lung
cancer treated at our institution with definitive radiation therapy with or without concurrent
chemotherapy (CHT). All patients were treated with 3D-CRT, including nodal regions determined
by CT or PET to be disease involved. Concurrent platinum-based CHT was administered for locally
advanced disease. Patients were analyzed in follow-up for survival, local regional recurrence, and
distant metastases (DM).
Results: The median follow-up time was 18 months (3 to 44 months) among all patients and 27
months (6 to 44 months) among survivors. The median overall survival, 2-year actuarial overall
survival and disease-free survival were 19 months, 38%, and 28%, respectively. The majority of
patients died from DM, the overall rate of which was 36%. Of the 31 patients with local regional
failure, 26 (22.6%) had IFF, 5 (4.3%) had ENF and 2 (1.7%) had isolated ENF. For 88 patients with
stage IIIA/B, the frequencies of IFF, any ENF, isolated ENF, and DM were 23 (26%), 3 (9%), 1 (1.1%)
and 36 (40.9%), respectively. The comparable rates for the 22 patients with early stage node-
negative disease (stage IA/IB) were 3 (13.6%), 1(4.5%), 0 (0%), and 5 (22.7%), respectively.
Conclusion: We observed only a 4.3% recurrence of any ENF and a 1.7% recurrence of isolated
ENF in patients with NSCLC treated with definitive 3D-CRT without prophylactic irradiation of
uninvolved lymph node stations. Thus, distant metastasis and IFF remain the primary causes of
treatment failure and cancer death in such patients, suggesting little value of ENI in this cohort.
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Background
In recent decades, it has been standard practice when
treating non-small cell lung carcinoma (NSCLC) to
deliver 40 to 50 Gy to the uninvolved regional lymph
nodes. Known as elective nodal irradiation (ENI), this
therapy is targeted to ipsilateral and contralateral hilar/
mediastinal nodes and occasionally to supraclavicular
areas, with an additional 20 Gy delivered to the primary
gross tumor through reduced fields [1].
In the era of 2-dimensional radiotherapy before the
advent of positron emission tomography (PET) scanning
for staging and before the use of adjunctive chemotherapy
(CHT), Radiation Therapy Oncology Group (RTOG) stud-
ies had shown a potential survival benefit from ENI in
stage III NSCLC [1]. The staging of regional lymph node
involvement has been greatly enhanced with the help of
PET. The addition of PET to clinical mediastinal staging
with CT has improved sensitivity and specificity com-
pared with CT alone. More accurate clinical staging with
PET allows the radiation oncologist to include involved
hilar and mediastinal nodes that were not visualized on
the CT scan and thereby reduce the probability of elective
nodal failure (ENF) [2]. Therefore, the concept of ENI has
been challenged with recent data showing very low rates
of elective nodal failure (ENF) using only involved-field
radiation therapy (IFRT) without ENI in the era of com-
puted tomography (CT)-based 3-dimensional conformal
radiotherapy (3D-CRT) [3].
However, these results have been met with caution, and a
recent survey reported that only 26% of the members of
the American Society of Therapeutic Radiation Oncology
treat NSCLC without ENI [4]. The most recent analysis of
the pertinent literature conducted by the International
Atomic Energy Agency concluded that the indication for
ENI in such cases is uncertain [5]. It appears that more
studies are needed to address this issue.
In our large single-institution study, we report the clinical
outcome and pattern of failure of 3D-CRT without ENI in
treating NSCLC after staging with PET scanning.
Methods
Patient selection and cancer staging
We retrospectively reviewed the clinical records of all con-
secutive patients who began their external beam radiation
therapy for NSCLC during 2002 at The University of Texas
M. D. Anderson Cancer Center. Patients were included for
analysis if they were diagnosed with histologically or cyto-
logically proven NSCLC not previously treated, received >
50 Gy definitive radiation to the primary tumor, had
tumors stage I to IIIB, had pre- and post-treatment CT
images available for review, and had complete radiation
treatment records. Patients who had multiple lobes in the
lung treated simultaneously were included based on the
assumption that their tumors consisted of synchronous
primary tumors. Disease was staged using chest CT and
brain magnetic resonance imaging (MRI) in all patients.
PET was also used for staging 75% of patients. Several
patients were treated on clinical protocols involving
induction or concurrent CHT. The majority of patients
with locally advanced disease received concurrent plati-
num-based CHT along with their radiation therapy. This
study was conducted with the approval of the Institu-
tional Review Board (study RCR05-0263).
Radiation treatment
Patients were treated using 3D conformal techniques
planned using CT-based Pinnacle planning software
(Philips Medical System, Andover, MA). Patients were
treated in the supine position with their arms raised above
their heads and were immobilized using a custom-made
Vac-Lok cradle (Medtec, Orange City, IA). Gross tumor
volume (GTV) was delineated based on the assessment of
abnormalities in the CT images. We focused on the lung
window to assess lung parenchymal disease and on the
mediastinal window to assess lymph node and mediasti-
nal involvement. When PET or PET/CT images were avail-
able, metabolically active lymph nodes were included in
the GTV even if they appeared grossly normal on CT. Like-
wise, involved nodal regions diagnosed by histologic eval-
uation of biopsies taken during mediastinoscopy were
also included in the GTV. Suspicious lymph nodes (> 1 cm
in the shortest dimension) were included as well.
Clinical target volume was defined as the GTV plus an 8-
mm margin to account for microscopic disease. First-ech-
elon lymph nodes were included in the clinical target vol-
ume in some cases, if they were visible and adjacent to the
gross disease and if coverage of these nodes did not ele-
vate normal tissue toxicity significantly, as decided on an
individual basis by the radiation oncologist. For the right
mid lobe or right lower lobe, left lingular, or left lower
lobe lesion, if a mediastinal lymph node was involved, the
ipsilateral hilar and subcarinal lymph nodes were treated
to 45–50 Gy. For a left upper lobe lesion, the aorto-pul-
monary window lymph node were treated to 45–50 Gy if
there was mediastinal lymph node involvement. Other-
wise uninvolved elective nodal regions that might previ-
ously have been considered eligible for prophylactic
treatment were excluded. Tumor motion was evaluated
based on location, clinical judgment, and x-ray fluoros-
copy. Another 10- to 15-mm margin was added to the
planning target volume to take tumor motion and set-up
uncertainty into consideration. Correction was made for
tissue inhomogeneity in all treatment plans. Treatment
was delivered using 6-MV or higher X-rays from a linear
accelerator and typically consisted of three or four treat-
ment fields, depending on the location of the tumor.Radiation Oncology 2009, 4:5 http://www.ro-journal.com/content/4/1/5
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Clinical endpoints
Clinical endpoints examined included overall survival,
disease-free survival, locoregional recurrence, and distant
metastasis (DM). At follow-up, patients were given chest
CT scans every 3 months for 2 years and then every 6
months for 3 years. PET scans were commonly used to
evaluate treatment response 3 to 6 months after the com-
pletion of radiotherapy and/or CHT. Clinical responses
were evaluated using Response Evaluation Criteria in
Solid Tumors (RECIST) based on both PET and CT images
[6]. Local tumor recurrence was defined as progressive
abnormal CT images corresponding to avid lesions on
PET images obtained during routine patient follow-up.
When a failure was noted in the clinical record, all imag-
ing prior to that time was carefully reviewed and the date
of failure coded based on the date the recurrence was first
visible radiographically. Locoregional recurrences were
classified as IFF if the majority of the recurrent tumor vol-
ume or an obvious origin of tumor recurrence was located
within the radiation treatment field PTV. Locoregional
failures were coded even if they occurred subsequent to
DM. ENF was defined as any recurrence outside the treat-
ment volume but located within bilateral hila, mediasti-
nal lymph node regions, and bilateral supraclavicular
areas (for upper lobe lesions). Isolated ENF was consid-
ered only in the absence of IFF and DM.
In cases of ENF, the site of recurrence was superimposed
on the original treatment planning CT images and a recur-
rent tumor volume approximated. The mean dose
received by this volume during the original treatment was
determined using the treatment planning software to esti-
mate dose to the nodal region that experienced recur-
rence. IFFs were presumed to have received the fully
prescribed treatment dose.
Statistics
Durations of survival and time-to-failure were determined
from the date of pathologic diagnosis, and survival prob-
abilities were determined by the Kaplan-Meier method
using JMP 6.0.3 for Macintosh (SAS Institute, Cary, NC).
Patients for whom the cause of death was unknown were
coded as dead of disease. Timing of recurrence was scored
at the time of the first image (PET and/or CT) that showed
abnormalities.
Results
Patient population and treatment
Table 1 shows the characteristics of 115 consecutive
patients with stage I to III NSCLC treated with 3D-CRT in
2002 at our institution (Table 1). The median follow-up
time was 18 months (range, 3 to 49 months). The major-
ity of patients had good performance status, with 89% cat-
egorized as either ECOG 0 or 1. Eighty-eight (77%)
patients presented with locally advanced (stage III) dis-
ease and 80 (91%) patients received concurrent CHT as
part of their treatment. Forty-four (38%) patients partici-
pated in prospective clinical trials. Radiation doses ranged
from 58 to 69.6 Gy, with the majority of patients treated
with either 63 Gy in 35 or 60 Gy in 30 daily fractions with
Table 1: Patient characteristics (N = 115)
Median age, years (range) 65 (35 – 92)
Median follow-up, months (range) 18 (3 – 49)
Sex (%)
male 58 (50)
female 57 (50)
ECOG performance status (%)
03 1  ( 2 7 )
17 1  ( 6 2 )
28  ( 7 )
31  ( 1 )
Unknown 4 (3)
Weight loss before treatment (%)
≥ 10% 24 (21)
< 10% 91 (79)
AJCC stage grouping (%)
IA/IB 22 (19)
IIA/IIB 5 (4)
IIIA 34 (30)
IIIB 54 (47)
Comorbidities (%)
COPD 30 (26)
Cardiovascular disease 59 (52)
Smoker 100 (87)
Pathologic classification (%)
Adenocarcinoma 43 (37)
Squamous cell carcinoma 39 (34)
Large cell carcinoma 3 (3)
Mixed 2 (2)
Non-small cell not otherwise specified 28 (24)
Grade (%)
Well-differentiated 7 (6)
Moderately differentiated 12 (10)
Poorly differentiated 55 (48)
No grade indicated 41 (36)
Location (%)
Right 63 (54)
Left 49 (43)
Mediastinal nodal disease only 3 (3)
Staging workup (%)
PET scan performed 86 (75)
Mediastinoscopy performed 16 (14)
Chemotherapy (%)
Induction 55 (47)
Concurrent
Taxane/platinum based 62 (54)
Other 18 (16)
Treated on clinical protocol (%) 44 (38)
Radiation treatment (%)
Mean dose 64 Gy
> 66 Gy 8 (7)
> 63 – 66 Gy 29 (25)
60 – 63 Gy 75 (65)
< 60 Gy 3 (3)
Mean treatment duration (days) 45Radiation Oncology 2009, 4:5 http://www.ro-journal.com/content/4/1/5
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concurrent CHT for stage III disease, 66 Gy in 33 daily
fractions without CHT for stage 1 disease, or 69.6 Gy given
as 1.2 Gy/fraction twice a day with concurrent CHT for
stage III disease in the superior sulcus location.
A total of 115 patients (58 men and 57 women) were ana-
lyzed in this study, including 27 stage I/II and 88 stage
IIIA/B cases. The median age at diagnosis was 65 years
(range, 35 to 92). As noted, 75% of patients underwent
PET for staging. Also, 70% of all patients and 85% of
patients with stage IIIA/B disease received concurrent,
platinum-based CHT.
Clinical outcome and pattern of failure
The median follow-up time was 18 months (3 to 44
months) among all patients and 27 months (6 to 44
months) among survivors. The median overall survival
duration and 2-year actuarial overall survival and disease-
free survival percentages were 19 months, 38%, and 28%,
respectively (Figure 1 and Table 2).
The leading cause of death among the patients was DM
and the overall rate of DM was 36%. Of the 31 patients
with local regional failure, 26 (22% of patients overall)
had IFF. The other 5 patients (4.3% of all patients) devel-
oped ENF (Tables 3, 4 and Figure 2). Two of the 5 patients
(1.7% of the overall group) developed isolated ENF as the
first site of failure, whereas the other 3 patients developed
in-field recurrence followed by out-of-field recurrence
(any ENF). All of the elective nodal failures occurred in
regions that did not receive a therapeutic dose of inciden-
tal radiation (> 45 Gy, Table 4). The Representative cases
of ENF were shown in Figure 2. The locations of recur-
rence were mixed and not clearly predictable on the basis
of the location of the primary tumor. For all 88 patients
with stage IIIA/B, the frequency of IFF, ENF, isolated ENF,
and DM were 23 (26%), 3 (3.4%), 1 (1.1%), and 36
(40.9%), respectively. Of the 27 patients with early-stage
node-negative disease (stage IA/IB), 3 had IFF (11.1%), 1
had ENF (3.7%), 0 had isolated ENF (0%), and 5 had DM
(18.5%). All 5 patients with ENF underwent PET for stag-
ing, and 1 of these patients was alive at the last follow-up
(at 44 months).
Discussion
Using PET for staging and treatment design, we found that
definitive 3-D radiotherapy without ENI was associated
with less than 2% isolated ENF in our study. IFRT alone
appears adequate for inoperable NSCLC. The main ration-
ale for foregoing ENI is that gross disease is not being con-
trolled according to the high local recurrence rates (22%)
within the previously irradiated tumor volume and the
high rates of DM (36%). If gross disease cannot be con-
trolled, then enlarging the irradiated volumes to include
areas that might harbor microscopic disease seems unnec-
essary. Three major factors have changed since RTOG 73-
01 established standard irradiation doses and volumes
(including ENI): the advent of CT-based 3D-CRT, the use
of chemotherapy, and better staging and target delinea-
tion using PET.
Emerging clinical data show that omitting prophylactic
lymph node irradiation does not reduce the local control
rate for patients receiving definitive radiotherapy, with
isolated ENF rates of 0% to 8% [5]. Rosenzweig and col-
leagues recently published results for a series of 524
patients treated definitively with 3D-CRT targeted to
involved-field volumes without ENI [7]. Only 6.1% of
Pattern of failure Figure 1
Pattern of failure. A. Probability of any disease recurrence by Kaplan-Meier method. B. Pattern of Failure. Distant metastasis 
(DM) remains the most common site of disease failure, followed by IFF and any ENF (p < 0.0001, log-rank test). Five of 115 
patients developed ENF and only 2 of 5 ENFs were isolated ENFs.
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patients suffered isolated ENF, while 49% developed IFF.
Belderbos et al also reported a 3% isolated ENF rate in
patients with PET-staged NSCLC receiving dose-escalated
radiotherapy without ENI [8]. Senan and colleagues
reported no ENF in patients with stage III disease treated
with 70 Gy of radiation without ENI [9]. A recently pub-
lished randomized trial also supported the benefit of
IFRT, with improved overall survival using dose-escala-
tion in the IFRT arm but not in ENI arm [10]. The multi-
center study RTOG 9311 also showed that only 6.7%
patients developed isolated ENF in NSCLC treated with
dose-escalated 3D-CRT without ENI [11].
The explanation for these lower-than-expected ENF rates
could be twofold. First, incidental doses to the ipsilateral
hilum, paratracheal, and subcarinal nodes approach 40 to
50 Gy when these regions are not intentionally irradiated
[12]. Second, lung cancer patients have multiple compet-
ing causes of mortality, including cancer and underlying
comorbid illnesses. Patients may die of local failure, dis-
tant failure, or intercurrent illness without detection of
ENF. Therefore, considering the high percentages of IFF/
DM and the short duration of overall survival using the
current dose (60 to 70 Gy) and technique (3D-CRT) of
therapy, the very low rate of isolated ENF justifies the use
of IFRT alone in NSCLC.
PET scanning used for staging in our study may explain
our very low rate (1.7%) of isolated ENF compared with
other studies that did not use PET scans [5]. In addition,
our recent published data has shown that tumor size and
PET standardized uptake value (SUV) predicted the
chance of IFF accurately [13]. In NSCLC, the chance of IFF
was 100% when the SUV for lymph node(s) was above
13.8 compared with 15% when the SUV was less than or
equal to 13.8 [13]. We found the SUV of the primary
tumor to have the same predictive value. Thus, in patients
with NSCLC, it is important to deliver adequate doses of
radiation to the involved nodal or mediastinal areas, par-
ticularly those areas with high SUVs. Adjusting the dose to
deliver higher levels of radiation to high-SUV areas seems
to be indicated.
Efforts to improve local control in patients treated with
radiation therapy for NSCLC have led to the development
of dose escalation strategies and concurrent chemoradio-
therapy. However, significant toxicities are associated
with dose escalation and concurrent CHT and, therefore,
Table 2: Patient outcomes (N = 115).
Overall survival*
Median (months) 19
1-yr (%) 72
2-yr (%) 38
Distant metastasis-free survival*
Median (months) 35
1-yr (%) 90
2-yr (%) 60
Local control*
Median (months) not reached
1-yr (%) 83
2-yr (%) 60
Disease-free survival*
Median (months) 14
1-yr (%) 63
2-yr (%) 28
* Kaplan-Meier method.
Representative coronal reconstructions from planning CT images demonstrating locations of ENF Figure 2
Representative coronal reconstructions from planning CT images demonstrating locations of ENF. The green 
contour represents ENF. The approximate location of the recurrences based on diagnostic CT imaging performed at the time 
of the recurrence is indicated (shaded area). A. Patient #4, isolated ENF. B. Patient #5, not isolated ENF. Refer to Table 4 for 
details regarding the sites of primary disease and recurrences.
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ENI needs to be minimized [14]. However, evolution of
the increasingly conformal treatment approaches such as
IMRT and proton therapy may reduce incidental doses to
the elective nodal region [15]. The data from our undergo-
ing clinical trials using IMRT or proton therapy in stage III
NSCLC will provide valuable information about the
impact of incidental doses on ENF. In addition, as we
improve our clinical outcomes (with lower rates of IFF
and longer survival) with dose escalated radiotherapy and
concurrent CHT, we should re-analyze the ENF data. As
patients survive longer and IFF is reduced, the microscopic
disease in the elective nodal region may become a greater
issue.
In our study, the low rates of isolated ENF were not a con-
sequence of unusually high rates of IFF, which can reduce
the observed rate of isolated ENF. The 1- and 2-year local
control rates of 83% and 60% were comparable to those
previously reported [11]. The pattern of ENF does not sug-
gest any needed modifications to the treatment fields. The
ENFs occurred in patients of diverse stages, treatment
approaches, and tumor locations. Only 2 of the 5 patients
with ENF developed recurrences in next order draining
lymphatics. Furthermore, of the 5 ENFs, 3 occurred after
IFF and may represent the spread of in-field recurrences
rather than true ENF.
In this study, the target volume was generally restricted to
involved regions, with some of the first-echelon nodes
treated if they were visible and adjacent to gross disease
and if coverage of these nodes would not change normal
tissue toxicity significantly, as decided on an individual
basis by the radiation oncologist. This approach was sup-
ported by the observation that the highest rates of
micrometastatic disease in mediastinal lymph nodes
occurred nearest to the tumor, mainly in peribronchial
and hilar locations [16]. Many factors are currently con-
sidered in the decision to include first-echelon nodes,
such as imaging characteristics of the lymph nodes, prox-
imity to the primary tumor, and the ability to meet dose
constraints. Recently, endobronchial ultrasound-guided
transbronchial needle aspiration (EBUS-TBNA) has
become widely used to stage mediastinal lymph nodes.
Dr. Herth et al [17] reported that EBUS-TBNA detected
lymph node involvement in 9/97 patients with clinical
stage I NSCLC with a normal CT image and negative PET
of lymph node areas. EBUS-TBNA may be considered to
verify the lymph node involvement for suspicious lymph
nodes in GTV delineation. This procedure may further
improve the accuracy of lymph node staging and target
delineation. It should be noted, however, that the sensi-
tivity of EBUS-TBNA is about 90% and common lymph
node stations sampled are level 2, 4, 7, 10 and 11 but not
level 5, 6, 8 and 9.
Table 3: Disease recurrence pattern.
N (%)
First site of failure (56 failures among 115 patients)
Isolated Elective nodal failure 2 (1.7)
In-field failure 18 (15.7)
Distant metastasis 36 (31.3)
Any Elective nodal failures (isolated and non-isolated) 5 (4.3)
Stage I/II 2
Stage III 3
Table 4: Patient characteristics for patients with any failures in elective nodal regions
Patient 
with ENF
T-Stage N-Stage Pathologic 
diagnosis
Primary tumor 
location
Dose (Gy) Chemotherapay Site of failure Dose to failure 
site (Gy)
1 2 1 Squamous Left hilum 60 None Right 
supraclavicular*
< 1.0
2 4 3 Adenocarcinoma Left lower lobe 63 Concurrent 
carboplatin/
paclitaxel
Ipsilateral 
mediastinum
22.5
3 2/1 0/0 Adenocarcinoma Left lower lobe/
right upper lobe†
66 None Left hilum, Left 
supraclavicular, 
Right 
supraclavicular
23.3, 24.4, 
44.3
4 2 3 Adenocarcinoma Right upper lobe 60 Induction and 
concurrent 
carboplatin/
paclitaxel
Right 
supraclavicular*
10.7
5 2 3 Squamous Right upper lobe, 
contralateral 
mediastinum, right 
hilum
63 Concurrent 
carboplatin/
paclitaxel
Left hilum 30.4
* Site of first failure in isolated elective nodal region.
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Conclusion
In the current era of PET-guided radiation treatment plan-
ning and 3D-CRT, restricting the target volume to
involved nodal regions results in minimal (< 2%) isolated
ENF. ENI does not appear to be indicated for unresectable
NSCLC. Future strategies should continue to be directed at
improving in-field control and preventing distant meta-
static disease.
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